DIACOMIT

Indicated For

Dravet syndrome

About This Medication

# Biocodex By Your Side Long-Term Patient Assistance Program Patient Guide: How to Get DIACOMIT (stiripentol) at Low or No Cost ## About DIACOMIT (stiripentol) **DIACOMIT (stiripentol)** is an FDA-approved medication specifically indicated for treating seizures associated with **Dravet syndrome** in patients 6 months of age and older weighing at least 7 kg.[1][6] Dravet syndrome is a rare, severe form of epilepsy that typically begins in infancy and can lead to frequent, prolonged seizures that are hard to control with standard treatments. Stiripentol works by enhancing the activity of GABA, a neurotransmitter that calms overactive brain signals, helping to reduce seizure frequency and severity when used alongside clobazam and other therapies.[1][6] This oral medication is taken three times daily (TID) with food, with dosing based on body weight—typically 50 mg/kg/day divided into three doses.[3] Common side effects include decreased appetite, weight loss, insomnia, and agitation, so regular monitoring by your healthcare provider is essential. Patients with phenylketonuria (PKU) should note it contains aspartame.[6] Always follow your doctor's instructions, as DIACOMIT is part of a Risk Evaluation and Mitigation Strategy (REMS) program to ensure safe use.[2] Biocodex, the manufacturer, understands the challenges of managing Dravet syndrome and offers comprehensive support through their **Biocodex By Your Side** programs, including this Long-Term Patient Assistance Program (PAP).[1][2][5] ## Who Qualifies for the Program? The **Biocodex By Your Side Long-Term Patient Assistance Program** provides **DIACOMIT at no cost** to eligible patients who are **uninsured or underinsured** and meet certain criteria.[1][2][5][9] This program is designed for those facing financial barriers to accessing this critical therapy for Dravet syndrome. Key eligibility factors include: - Confirmed diagnosis of Dravet syndrome (prescription required from your healthcare provider).[3] - Uninsured status or underinsured (e.g., high copays or coverage gaps that make the medication unaffordable).[1][9] - U.S. residency (program serves patients in the USA).[5] **Income Eligibility Breakdown** Specific income thresholds (e.g., Federal Poverty Level percentages) are not publicly detailed; eligibility is determined case-by-case based on financial need, insurance status, and other criteria.[1][5][9] Contact the program for a personalized assessment. Here's a general overview: | Household Size | Estimated Income Threshold | Notes | |---------------|----------------------------|-------| | Individual | Case-by-case review | Must demonstrate financial need; no fixed FPL listed. | | Couple | Case-by-case review | Uninsured/underinsured prioritized. | | Family of 3 | Case-by-case review | Focus on Dravet patients unable to afford meds. | | Family of 4+ | Case-by-case review | Household income and expenses evaluated. | *Table based on program notes; call 833-248-0467 for exact qualification.*[1][5] ## Insurance Requirements This program targets **uninsured or underinsured patients**.[1][2][9] "Underinsured" typically means you have insurance but face high out-of-pocket costs, denials, or gaps in coverage. It's **not available for government plans like Medicare or Medicaid**—other programs like the Copay Program may apply for commercial insurance.[6][8] The Biocodex team can help investigate benefits, prior authorizations, and appeals.[1][2] If you're commercially insured, explore the Copay Program for $0 copays. For insurance lapses, the Bridge Program offers up to 60 days of free medication.[5][6][8] ## Step-by-Step Application Process 1. **Consult Your Doctor**: Discuss your Dravet syndrome treatment and confirm DIACOMIT is appropriate. Your healthcare provider must complete the prescription section.[3] 2. **Download the Form**: Get the **Patient Enrollment Form** from the program's website: [Patient Enrollment Form](https://www.diacomit.com/wp-content/uploads/2024/05/Patient-Enrollment-Form_March-2024-Update_508.pdf).[3] 3. **Gather Documents**: - Completed **Patient Enrollment Form** (patient and doctor sections).[3] - Valid **prescription** for DIACOMIT from your provider.[3] 4. **Submit by Fax**: Fax everything to the designated number (provided on form; HCP faxes to 833-871-4137).[9] Application method is fax.[program details] 5. **Call for Help**: Contact the **Biocodex By Your Side Support Team at PANTHERx** at **(833) 248-0467** (Mon-Fri, 8 AM-8 PM ET) for questions, eligibility checks, or assistance.[1][2][3][9] The team offers 24/7 pharmacist support, translation in 100+ languages, and help with prior authorizations.[1][2] ## Timeline and Delivery Processing time varies but aims to be efficient; a **Quick Start Program** provides up to 60 days of free DIACOMIT for delays.[5][6][8] Once approved, medication is **shipped directly to your door** via PANTHERx Rare Pharmacy, with tracking and vacation planning to avoid missed doses.[1][2][program details] **Reauthorization is required** periodically—your doctor will be proactively contacted for refills.[1][2][program details] Opt into the Rapid Refill program for online/mobile scheduling.[2] Free dosing supplies (syringes, cups) available on request.[1][2] ## Alternatives if Denied - **Appeal**: The support team assists with insurance appeals.[1] - **Other Biocodex Programs**: Quick Start (new patients, 60 days free), Bridge (insurance gaps, 60 days), Copay ($0 for commercial insurance).[5][6][8] - **General Resources**: Check PANTHERx or sites like GoodRx for additional PAPs, though DIACOMIT-specific options are limited.[7] - **Contact Support**: Call 833-248-0467 immediately for guidance.[2] No biosimilar alternatives exist for stiripentol.[program details] ## Important Disclaimer This guide is for informational purposes only and based on publicly available data as of 2024-2025.[1][2][3][5][6] Eligibility, terms, and availability can change—**always verify with the program at 833-248-0467**. Not medical advice; consult your healthcare provider for treatment decisions. Biocodex and PANTHERx reserve the right to modify programs. Patients must meet all criteria, and approval is not guaranteed.

Program information last verified: March 30, 2026